CoChat

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Ursodeoxycholic acid (UDCA) treatment has been shown to increase survival without orthotopic liver transplantation (OLT) in patients with primary biliary cirrhosis (PBC) at 4 years. Whether this beneficial effect was maintained over the long term remained to be established. In a large cohort of UDCA–treated patients with PBC, we aimed to determine the 10–year outcome of these patients using two endpoints: (1) survival without OLT, and (2) survival. The cohort was comprised of 225 patients with PBC treated with UDCA (13–15 mg/kg/d) monitored from the beginning of treatment until time of last follow–up, OLT, or death. Because of the absence of a control group, survival without OLT was compared with survival predicted by the Mayo model (first 7 years), and observed 10–year survival with an estimation of survival of a standardized control cohort of the French population. Observed survival without OLT of UDCA–treated patients was significantly higher (P < .04) than survival predicted by the Mayo model. Observed survival was significantly lower (P < .01) than survival predicted from the French population. Observed survival of noncirrhotic patients was not different (P > .9) from that of the French control population but survival of cirrhotic patients was significantly lower (P < .0001). Twenty–two patients died; 13 patients died of hepatic causes and 4 patients died after OLT. In conclusion, survival without OLT among patients treated with UDCA for PBC is higher than that of untreated patients, as predicted by the Mayo model. Ten–year survival among UDCA–treated patients is slightly lower than that of an age– and sex–matched general population, the difference mainly being explained by mortality among cirrhotic patients

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.510290603

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Research works printed but not linked: 2

  1. Combes, 1995, A randomized, double-blind, placebo-controlled trial of ursodeoxycholate in primary biliary cirrhosis, Hepatology, 22, 759
  2. Poupon, 1997, Bile acids and Immunology, 241

Cited by

See all 213

Metadata

Authors
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R.
Affiliations
Inserm (FR)
Corresponding author
Poupon, Renée Eugénie
Venue
Hepatology
Published
1999-06
Volume
29
Issue
6
Pages
1668-1671
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2048473231
Cited by
209
References
19
Citations by year
2026: 4 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 6 · 2012: 11
FWCI
6.58
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 5936 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
PHRC, Assistance Publique-Hôpitaux de Paris (AOM 96045)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
primary biliary cirrhosis, ursodeoxycholic acid, long-term survival, liver transplantation, Mayo risk score, mortality, cirrhotic patients, non-cirrhotic patients, bile acid therapy
MeSH terms
Bilirubin, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Prothrombin Time, Serum Albumin, Time Factors, Ursodeoxycholic Acid, Cohort Studies, Survival Analysis, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. https://app.cochat.ai/papers/10.1002/hep.510290603
The paper
Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R. (1999). Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology. https://doi.org/10.1002/hep.510290603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.